# Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

> **NCT01650259** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 4876 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** OAD
- **DRUG:** Trazenta

## Key facts

- **NCT ID:** NCT01650259
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-23
- **Primary completion:** 2017-09-05
- **Final completion:** 2017-09-14
- **Target enrollment:** 4876 (ACTUAL)
- **Last updated:** 2019-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01650259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01650259, "Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01650259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*